Results 221 to 230 of about 18,780,434 (409)

Durable B‐Cell Impairment While Sparing IgA B Cells After Ocrelizumab Therapy in Multiple Sclerosis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives Ocrelizumab (OCR), a humanized anti‐CD20 monoclonal antibody, is highly efficient in relapsing–remitting multiple sclerosis (RR‐MS). We assessed early cellular B‐cell profiles in patients prior to OCR treatment, on OCR treatment, and after 15 months of therapy discontinuation.
Alexandra Garcia   +20 more
wiley   +1 more source

Childhood obesity beyond COVID-19

open access: yesThe Lancet Public Health, 2021
The Lancet Public Health
doaj  

Telemedicine and public health-pearls and pitfalls. [PDF]

open access: yesWorld J Methodol
Sinha RK   +4 more
europepmc   +1 more source

The Elements of Public Health Administration

open access: green, 1923
George Sparr Luckett, Harold F. Gray
openalex   +2 more sources

Digital Activity Markers in Chronic Inflammatory Demyelinating Polyneuropathy

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the utility of smartwatch and smartphone‐based activity metrics for assessing disease severity and quality of life in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). Methods In the electronic monitoring of disease activity in patients with CIDP (EMDA‐CIDP) trial, we performed a prospective ...
Lars Masanneck   +15 more
wiley   +1 more source

Income, health, and social welfare policies

open access: yesThe Lancet Public Health, 2020
The Lancet Public Health
doaj  

Reinvigorating the public health response to dementia

open access: yesThe Lancet Public Health, 2021
The Lancet Public Health
doaj  

Home - About - Disclaimer - Privacy